Bringing Medicines to Market Faster Through Analytics & Machine Learning

 

Traditional medicine isn’t generally taken very seriously in the United States. However, Dr. Andrea Small-Howard, President and CSO at GB Sciences explained that “65% of the world still use traditional medicine either as their sole medicine or in conjunction with Western medicine.” Depending on the source, traditional plant-based medicine dates back as far as 60,000 years whereas Western medicine is a mere 3,000 years old.

Kevin Stevenson, I Don’t Care podcast host, sat down with the distinguished Dr. Small-Howard to discuss her work in the plant-based medicine industry. Dr. Small-Howard will also discuss the digital transformation curve with GB Sciences AI-based drug discovery platform PhAROS. This podcast is of great interest due in part to Dr. Small-Howard’s extensive resume. In fact, it is so extensive that the following introduction from her LinkedIn profile barely highlights her expertise.

“Dr. Andrea Small-Howard has 25 years of scientific research and executive experience in the biopharma industry supervising research & development, manufacturing, and quality control divisions in the US and China. Dr. Small-Howard has taken novel biological products from ideation through commercialization. She has been named an inventor on seventy+ patent applications, taken the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration (‘US FDA’), and orchestrated commercial licensing deals.”

Listeners might think that they would not be able to understand or relate to such a well-educated scientific mind, but nothing could be further from the truth. Dr. Small-Howard is an engaging speaker filled with enthusiasm for her chosen line of work and her mission to normalize plant-based medicine in the United States.

“My background is in biochemistry, so I sort of see the world through a different lens and I’ve always been obsessed with the power of plant-based medicines. Traditional medicine is often overlooked as being a really powerful force here in the United States,” said Dr. Small-Howard. The doctor joined GB Sciences in 2014 to take plant-based medicine to the next level by utilizing science to maximize the potential of the cannabis plant.

More Like This Story:

Behavioral Health Is Stepping Out of the Shadows of Healthcare

Tearing Down the Barrier of Prior Authorization Through Automation

Follow us on social media for the latest updates in B2B!

Image

Latest

courage
Creative Confidence and Moral Courage: The Leadership Traits Business Schools Should Be Betting On
May 25, 2026

What students need from higher education is becoming harder to pin down than it once was. As higher education faces mounting pressure—from student disengagement to the rapid rise of artificial intelligence—institutions are being forced to rethink not just what students learn, but who they become. New research and industry signals suggest that technical knowledge…

Read More
healthcare
From the C-Suite to the Classroom: A Healthcare Leader’s Bet on the Next Generation
May 25, 2026

Healthcare isn’t short on strategy right now—it’s short on people, access, and experienced leadership where it matters most. In Texas alone, more rural hospitals have closed than in any other state over the past decade, leaving entire communities with limited access to care. At the same time, many health systems are realizing they haven’t…

Read More
AI
The AI Health Score: Turning Hallucinations, Agents, and AI Risk Into Board-Ready Insight
May 24, 2026

As artificial intelligence moves deeper into enterprise operations, many organizations are discovering that the real challenge is not adoption, but control. Traditional software has always been predictable: the same input produces the same output, making it possible to audit systems at a fixed point in time. AI changes that equation. Jeff Carson, founder of…

Read More
TheAIAudit
Introducing TheAIAudit: A Platform Built to Measure, Monitor, and Govern Enterprise AI
May 22, 2026

Enterprise AI is advancing faster than most companies can govern it. Behind the scenes, AI systems are already influencing decisions tied to revenue, operations, compliance, customer outcomes, and risk — yet many organizations still lack a clear way to measure, explain, or oversee what those systems are doing. That is the gap TheAIAudit was…

Read More